Research Library — Page 45 | Reta Compare
3563 research articles. Page 45 of 143.
Articles
- The Lilly 'Safety Doesn't Discount' Campaign
- Case Consolidation in Lilly Compounded Tirzepatide MDL Discussions
- Lilly's Subpoenas to API Suppliers in Compounded Cases
- How Lilly Coordinates with Novo Nordisk on Shared Issues
- Lilly's Pursuit of Import Records for Foreign API
- Lilly's Discovery Requests for Prescription Records
- Regulatory-Litigation Interaction: Lilly Cases After FDA Warning Letters
- Lilly's Policy Lobbying on Compounded Peptide Legislation
- The Compounding Industry's Response to Lilly Enforcement
- Overview: Peptides and the Schedule II Debate
- RFK Jr. on Peptides: Public Statements and Interviews
- HHS Peptide Policy Review Under RFK Jr.
- DEA Scheduling of Peptide-Category Substances
- The 'Coming Off Schedule II' Narrative for Peptides
- BPC-157 and Regulatory Status in 2026
- TB-500 and the 2026 Scheduling Debate
- CJC-1295 and Ipamorelin in 2026 Policy Discussions
- RFK Jr.'s HHS Staff on Peptide Policy
- Federal Research Peptide Policy in 2026
- Peptide Industry Response to RFK Jr.'s Agenda
- Public Comments to HHS Peptide Policy Review
- Peptide Legislation in the 119th Congress
- RFK Jr. on the Joe Rogan Experience: Peptide Discussion
- State-Level Peptide Legislation in 2026
- RFK Jr. on FDA Reform and Peptides